Embecta Corp. (EMBC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Embecta Corp. (EMBC) Healthcare & Pipeline Overview

Embecta Corp. is a medical device company providing diabetes management solutions, including pen needles, syringes, and digital applications. Operating independently since 2022, Embecta focuses on serving wholesalers and distributors globally, positioning itself within the specialty and generic drug manufacturing sector with a strong emphasis on diabetes care.

What Is the Investment Thesis for EMBC?

Embecta Corp. presents a focused investment opportunity within the diabetes care market. With a P/E ratio of 3.28 and a dividend yield of 16.48%, the company demonstrates potential value. A gross margin of 62.5% indicates efficient operations. Growth catalysts include expanding digital application offerings and penetrating emerging markets. Potential risks involve competition from established medical device companies and regulatory changes impacting diabetes care products. Investors should monitor Embecta's ability to maintain its market share and adapt to evolving healthcare trends. The company's beta of 1.10 suggests a slightly higher volatility compared to the market.

Based on FMP financials and quantitative analysis

EMBC Key Highlights

Market capitalization of $290M indicates a mid-sized player in the medical device market.

• P/E ratio of 3.28 suggests the company may be undervalued compared to its earnings.
• Profit margin of 10.7% reflects the company's ability to generate profit from its revenue.
• Gross margin of 62.5% indicates efficient cost management in the production of its medical devices.
• Dividend yield of 16.48% offers a substantial return to investors, reflecting the company's commitment to shareholder value.

Who Are EMBC's Competitors?

EMBC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are EMBC's Key Strengths?

Focus on diabetes care solutions.

• Established distribution network.
• High gross margin (62.5%).
• Independent operation since 2022.

What Are EMBC's Weaknesses?

Reliance on wholesalers and distributors.

• Limited product diversification.
• Potential competition from larger medical device companies.
• Relatively small market capitalization.

What Could Drive EMBC Stock Higher?

Expansion of digital health solutions for diabetes management.

• Geographic market expansion into emerging economies.
• Development of new and innovative diabetes management products.
• Strategic partnerships and acquisitions to broaden product portfolio.
• Focus on patient education and support programs to enhance brand loyalty.

What Are the Key Risks for EMBC?

Financial-distress signal — its Altman Z-Score of 1.30 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-14.0%) — the business is not currently generating profit on shareholder capital.
• Regulatory changes impacting the diabetes care market.
• Competition from established medical device companies.
• Pricing pressures from healthcare providers and insurers.
• Economic downturn affecting healthcare spending.
• Supply chain disruptions affecting product availability.

What Are the Growth Opportunities for EMBC?

• Expansion of Digital Health Solutions: Embecta can leverage the growing demand for digital health solutions by enhancing its existing digital applications and developing new platforms for diabetes management. Timeline: Ongoing.
• Geographic Market Expansion: Embecta has the opportunity to expand its presence in emerging markets with a growing diabetes population, such as India and China. These regions represent significant growth potential due to increasing healthcare access and rising diabetes prevalence. This expansion could increase revenue streams and global market share over the next 3-5 years.
• New Product Development: Embecta can invest in research and development to create innovative diabetes management products, such as smart insulin pens and continuous glucose monitoring (CGM) devices. The global market for diabetes devices is expected to reach $30 billion by 2027, providing a strong incentive for new product development. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: Embecta can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with or acquiring companies specializing in diabetes technology or related healthcare services can enhance Embecta's competitive position and drive growth. Timeline: Ongoing.
• Focus on Patient Education and Support: Embecta can strengthen its relationships with healthcare providers and patients by offering comprehensive education and support programs. By providing resources and tools to help patients manage their diabetes effectively, Embecta can enhance brand loyalty and drive product adoption. Timeline: Ongoing.

What Are EMBC's Competitive Advantages?

• Established Brand: Embecta has a long-standing history and reputation in the diabetes care market.
• Specialized Expertise: The company possesses specialized knowledge and expertise in insulin delivery systems.
• Distribution Network: Embecta has an established distribution network, reaching a wide range of customers.
• Focus on Diabetes: As an independent company solely focused on diabetes care, Embecta can dedicate resources and attention to this specific area.

What Does EMBC Do?

Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey. Originally part of Becton, Dickinson and Company, Embecta spun off as an independent entity on April 1, 2022. The company is dedicated to enhancing the health and well-being of individuals living with diabetes through its comprehensive range of products. Embecta's core offerings include pen needles, syringes, and safety devices designed for insulin delivery, as well as digital applications aimed at assisting patients in managing their condition. These products are primarily distributed through wholesalers and distributors, reaching both domestic and international markets. With a focus on innovation and patient care, Embecta aims to be a leading provider of diabetes management solutions, leveraging its long-standing history and expertise in the medical device industry to address the evolving needs of the diabetes community. The company's independence allows it to focus specifically on diabetes care, fostering specialized product development and targeted market strategies.

What Products and Services Does EMBC Offer?

• Develop and manufacture pen needles for insulin delivery.
• Produce syringes for administering insulin and other medications.
• Offer safety devices to prevent needlestick injuries.
• Create digital applications to assist individuals in managing their diabetes.
• Distribute products through wholesalers and distributors.
• Provide solutions for enhancing the health and well-being of people living with diabetes.

How Does EMBC Make Money?

• Develops and manufactures medical devices for diabetes management.
• Sells products to wholesalers and distributors.
• Generates revenue through product sales in the United States and internationally.

What Industry Does EMBC Operate In?

Embecta Corp. operates within the drug manufacturers - specialty & generic industry, a segment experiencing growth due to the increasing prevalence of diabetes globally. The competitive landscape includes established medical device companies and pharmaceutical firms focusing on diabetes care. Market trends involve the development of advanced insulin delivery systems and digital health solutions for diabetes management. Embecta's focus on pen needles, syringes, and digital applications positions it to capitalize on these trends, addressing the needs of a growing patient population.

Who Are EMBC's Key Customers?

• Wholesalers of medical supplies.
• Distributors of medical devices.
• Healthcare providers.
• Pharmacies.

Embecta Corp. Financial Trajectory

Embecta Corp. (EMBC) reported $271.7M in revenue for Q3 FY2026, reflecting 22.5% growth compared to the prior quarter. The company recorded net income of $21.1M, with diluted EPS of $0.36. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, EMBC averaged $0.37 in diluted EPS.

Company Profile

Embecta Corp. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Parsippany, US. The company is led by CEO Devdatt Kurdikar. EMBC has traded publicly since 2022.

How Embecta Corp. Is Valued

Embecta Corp. carries a market capitalization of $290M, placing it in the micro-cap category. Analyst price targets span from $5.00 to $5.00, with a consensus of $5.00. At the current price of $4.89, that implies approximately 2% upside potential. Relative to its peer group, EMBC's quantitative score of 75/100 is above the peer average of 62/100.

Return on equity for Embecta Corp. stands at -14.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.9%, showing how much profit it generates from its asset base. EMBC trades at a trailing price-to-earnings ratio of 3.28, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 55.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 29.7%, the inverse of the P/E and a quick read on earnings relative to price.

Embecta Corp.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.30 places it in the distress zone, a signal of elevated financial risk.

Embecta Corp. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 34.3% above estimates on average.

Over the past six months, Embecta Corp. insiders filed 7 SEC Form 4 transactions — 2 sales and 5 purchases. On net that is roughly 137K shares acquired (about $514K) — insiders putting money in tends to read as conviction.

EMBC Financials

EMBC Latest News

EMBC Analyst Consensus

EMBC MoonshotScore

What Investors Ask About Embecta Corp. (EMBC) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources